Figure 2From: Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary careProportions of patients with 75 and 90% improvement in UAS7 and DLQI from baseline.Back to article page